Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Novelion Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a NaN upside from the last price of $0.00.
Current Consensus is
N/A
The current consensus among 0 investment analysts is to n/a stock in Novelion Therapeutics. This N/A consensus rating has held steady for over two years.
Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.
Read More